| abstract |
Disclosed are inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds have formulae IIIa and IIIb, wherein Cy is optionally substituted aryl or heteroaryl, R1 and R2 are optionally substituted alkyl, and the remaining substituents are as defined in the specification. The compounds can be useful in the treatment of various diseases associated with expression or activity of 11-beta hydroxyl steroid dehydrogenase type I and/or diseases associated with aldosterone excess. |